A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

Merck Sharp & Dohme (MSD)

Status and phase: Enrolling; Phase 1

Conditions: Healthy

Treatments: Drug: Enlicitide; Drug: MK-7262

Study type: Interventional

Funder types: Industry

Identifiers

NCT07619443

MK-7262-003 (Other Identifier)

7262-003

Details and patient eligibility

About

The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.

Enrollment: 30 estimated patients

Sex: All

Ages: 19 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

• Is in good health before randomization
• Has a body mass index (BMI) ≥18 and ≤32 kg/m^2, inclusive

Exclusion criteria

The main exclusion criteria include but are not limited to the following:

• Has a history or presence of clinically significant medical or psychiatric condition or disease
• Has a history of cancer

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

30 participants in 3 patient groups

MK-7262

Experimental group

Description:

Participants will receive MK-7262 orally.

Treatment:

Drug: MK-7262

Enlicitide

Experimental group

Description:

Participants will receive enlicitide orally.

Treatment:

Drug: Enlicitide

MK-7262 plus Enlicitide

Experimental group

Description:

Participants will receive MK-7262 and enlicitide orally.

Treatment:

Drug: MK-7262

Drug: Enlicitide